All In Biotech

Drug Trial Radar · NCT07908147

Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients - Pilot Study

Biomarker-guided RAdiation-deferring Treatment in Younger GBM Patients (BRAid GBM) Pilot Study

Last checked: Nov 20, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

12

Planned (sponsor's estimate)

Start

Mar 2027

Primary completion

Mar 2028

Study completion Mar 2028

Sponsor

Lead sponsor
Olivia Newton-John Cancer Research InstituteAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Fore Biotherapeutics; Akesobio Australia Pty Ltd
First posted
Oct 30, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Non randomized
Model
Single group
Masking
Single (investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will investigate whether rapid molecular testing of recurrent glioblastoma (GBM) can identify tumour biomarkers that may help guide treatment selection in younger people with IDH-wildtype GBM. Participants will be people under 55 years of age whose diagnosis is consistent with glioblastoma and who have undergone recent surgery or previously participated in the initial phase of the BRAid GBM study. Tumour tissue will undergo rapid molecular testing to identify biomarkers that may predict response to specific targeted treatments. Treatment decisions will be informed by the molecular characteristics of each participant's tumour and available evidence for treatments associated with the identified biomarkers. The study will assess the feasibility and safety of implementing rapid molecular testing across multiple Australian hospitals and whether this approach can provide timely information to support personalised treatment decisions. The study will also explore whether biomarker-guided treatment may provide alternatives to, or reduce the use of, radiotherapy in younger people with glioblastoma, with the potential to reduce long-term treatment-related effects on cognition and quality of life. Approximately 110 patients will be screened and 12 participants will be recruited from participating hospitals across Australia.

Conditions

  • IDH Wildtype Glioblastoma
  • Glioblastoma (GBM)

Interventions

  • LarotrectinibDrug

    Larotrectinib is a first-in-class, highly selective, oral inhibitor of the tropomyosin receptor kinase (TRK) family of proteins (TRKA, TRKB and TRKC).

  • CadonilimabDrug

    AK104 is bispecific IgG single chain Fv fragment (ScFv) monoclonal antibody that binds to human programmed cell death 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)

  • PlixorafenibDrug

    Plixorafenib is a next generation, orally available, small-molecule, selective inhibitor of Class 1 and 2 mutated BRAF.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Feasibility of Rapid Molecular Profiling and Matched Targeted TherapyTime frame: From enrollment to initiation of chemoradiation (pre-treatment period).

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Austin Hospital

    Heidelberg, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.